𝔖 Bobbio Scriptorium
✦   LIBER   ✦

β-secretase inhibitors for treatment of Alzheimer's disease

✍ Scribed by O'Neill, Brian T.; Brodney, Michael A.; Ambroise, Claude; Borzilleri, Kris; Coffman, Karen; Efremov, Ivan; Hajos-Korcsok, Eva; Helal, Christopher; Kauffman, Gregory; Lanyon, Lorraine; Liston, Dane; JianHua Liu, ; Lu, Yasong; Martinez-Alsina, Luis; Murray, John; Nelson, Frederick R.; Noell, Stephen; Nolan, Charles; Oborski, Christine; Ogilvie, Kevin; Tuttle, Jamison; Vajdos, Felix; Withka, Jane

Book ID
123179289
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
46 KB
Volume
6
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Boom in the development of non-peptidic
Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease
✍ Romano Silvestri 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

## Abstract β‐Amyloid cleaving enzyme‐1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non‐peptidomimetic β‐secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non‐